EUVIMED · CrossrefZeitschrift
Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector
ISSN 1741-1343 · SAGE Publications
Neueste Artikel
A review and analysis of product recall for pharmaceutical drug product
Effects of new formulation strategy on life cycle management in the US pharmaceutical industry
Opportunities and Challenges to Implementing Quality by Design Approach in Generic Drug Development
Price Comparison between Innovator and Generic Medicines Sold by Community Pharmacies in the State of Penang, Malaysia
Fluvastatin and Atorvastatin: A Comparison of Patent Protection (Part 2)
Fluvastatin and Atorvastatin: A Comparison of Patent Protection (Part 1)
EU Legal and Regulatory Update
Climate of Change Continues in Canada
Evaluating Community Pharmacists' Perceptions and Practices on Generic Medicines: A Pilot Study from Peninsular Malaysia
Abbott v Torpharm : The Contours of Contempt
EU Legal and Regulatory Update
Book Review
Tropical Disease Priority Review Vouchers: Potential Incentives and Opportunities for Generic Manufacturers
Prevailing against Cost-Leader Competitors in the Pharmaceutical Industry
Biogen Insufficiency Explained; Alendronate in Netherlands; Behaviour Relevant to Injunction; Perindopril Evergreening Criticised; ‘Negative Term’ SPCs'; New Dosage Regimes
Veterinary Generics: An Enigma among Niche Markets
Formulations Patents in Pharmaceutical Development
Continuing Equivalence: Is There an End to the Story?
Aventis v Lupin : Obviousness of Purified Stereoisomers in View of Mixtures Thereof
EU Legal and Regulatory Update
The Single Bioequivalence Study's Impact on the Dossier Broker
Standing up for Generic Manufacturers: The Increasing Ability to Challenge NDA Patents
Ortho-McNeil v Mylan : Multiple Summary Judgment Rulings for Patentee Including One on the Meaning of ‘and’
Patent-Related Barriers to Market Entry for Generic Medicines in the European Union: A Review of Weaknesses in the Current European Patent System and their Impact on Market Access of Generic Medicines
Give the Poor Patients a Chance: Enhancing Access to Essential Medicines through Compulsory Licensing
Patent Opinions and their Role in Developing Generic Medicines: A US Perspective
A Buyer's Guide to Generic Pharmaceutical Acquisitions
House of Lords Provides Guidance on the Law of Obviousness in Patent Actions; Increased Opportunities to Obtain Supplementary Protection Certificates for Combinations of Active Ingredients; Patent for DNA and Protein Sequence Invalid Due to Lack of Industrial Application
Supplementary Protection Certificates; Atorvastatin; Fexofenadine
Innovation through Generic Medicines: Is it Time for a Pan-European Policy?
EUVIMED